Xtclav Dry Syrup is a combination antibiotic formulation containing Amoxycillin 200 mg and Clavulanic Acid 28.5 mg per 5 ml of reconstituted suspension. Amoxycillin, a broad-spectrum penicillin antibiotic, exerts bactericidal activity by inhibiting bacterial cell wall synthesis, while Clavulanic Acid acts as a beta-lactamase inhibitor, enhancing the efficacy of Amoxycillin against beta-lactamase producing resistant bacterial strains. Xtclav Dry Syrup is indicated for the treatment of various bacterial infections including respiratory tract infections, otitis media, sinusitis, urinary tract infections, skin and soft tissue infections, and dental infections caused by susceptible organisms. The dry syrup formulation is particularly suitable for pediatric patients who require accurate dosing and ease of administration. Dosage and duration of therapy should be determined based on the severity of infection, patient age, and clinical response. It is essential to complete the full prescribed course to prevent the development of resistance. Xtclav Dry Syrup should be used with caution in patients with a history of penicillin allergy or hypersensitivity to beta-lactam antibiotics. Common adverse effects may include gastrointestinal disturbances such as diarrhea, nausea, and vomiting. Proper reconstitution and storage as per manufacturer’s instructions are critical to maintain drug stability and efficacy.